Correspondence 0001193125-24-151741 from KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: May 31, 2024 · CIK: 0001075880 · Accession: 0001193125-24-151741
AI Filing Summary & Sentiment
File numbers found in text: 333-279773
Letter
Re: Kazia Therapeutics Limited
May 31, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Acceleration Request for Registration Statement on Form F-1
File No. 333-279773
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kazia Therapeutics Limited (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 4, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Robert E. Puopolo of Goodwin Procter LLP at (617) 570-1393.
Sincerely,
KAZIA THERAPEUTICS LIMITED
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 31, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kazia Therapeutics Limited Acceleration Request for Registration Statement on Form F-1 File No. 333-279773 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kazia Therapeutics Limited (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 4, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Robert E. Puopolo of Goodwin Procter LLP at (617) 570-1393. Sincerely, KAZIA THERAPEUTICS LIMITED /s/ John Friend John Friend Chief Executive Officer and Managing Director cc: John Friend, Chief Executive Officer and Managing Director, Kazia Therapeutics Limited Robert E. Puopolo, Esq., Goodwin Procter LLP